Skip to content

Study · Not a test of the peptide alone · 1995

8 results

Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial.

Manesis EK, Giannoulis G, Zoumboulis P, Vafiadou I, Hadziyannis SJ

Hepatology (Baltimore, Md.)1 Jun 1995Cited by 87 (Europe PMC)

PMID7768497 (opens in a new tab)DOI10.1002/hep.1840210610 (opens in a new tab)PepBankPUB-07768497
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  1. 01HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialOther

    In HCC, the triptorelin plus tamoxifen regimen predicted survival in a Cox model.

    In plain wordsIn liver cancer, the triptorelin plus tamoxifen regimen predicted survival in a statistical model.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableTreatment as survival predictor
    Study

    n = 85

    Outcome group
    Mortality · Cancer

    Source sentences

    Summary
    In a Cox proportional hazards model, the TMX treatment, along with the baseline Okuda's HCC stage, the hepatitis B surface antigen, the portal vein diameter, the carcino embryonic antigen (CEA) and a self-assessment score of quality of life, were covariates predicting survival.
    1 context sentence
    Summary · context
    Eighty-five consequent, previously untreated HCC patients with inoperable disease, were randomized to receive the luteinizing hormone-releasing hormone (LR-RH)-analogue triptorelin and the antiestrogen tamoxifen (33 patients) or triptorelin plus the antiandrogen flutamide (23 patients), or only plac…

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  2. 02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome

    In inoperable HCC, triptorelin plus tamoxifen prolonged survival compared with placebo.

    In plain wordsIn inoperable liver cancer, triptorelin plus tamoxifen prolonged survival compared with placebo.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseSurvival versus placebo
    Study

    n = 62

    Comparator
    Placebo
    Outcome group
    Mortality · Cancer

    Measurements

    Survival
    282 days
    triptorelin plus tamoxifen
    Survival
    127 days
    placebo

    Source sentences

    Summary
    The tamoxifen (TMX) group had a significantly longer survival (282 days) compared with flutamide (112 days) and with placebo (127 days) groups (P = .0238, log rank test).
    1 context sentence
    Summary · context
    Eighty-five consequent, previously untreated HCC patients with inoperable disease, were randomized to receive the luteinizing hormone-releasing hormone (LR-RH)-analogue triptorelin and the antiestrogen tamoxifen (33 patients) or triptorelin plus the antiandrogen flutamide (23 patients), or only plac…

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  3. 03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome

    In HCC, triptorelin plus tamoxifen increased tumor volume doubling time compared with placebo.

    In plain wordsIn liver cancer, tumors doubled more slowly with triptorelin plus tamoxifen than with placebo.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseTumor volume doubling time versus placebo
    Study

    n = 62

    Comparator
    Placebo
    Outcome group
    Tumor growth · Cancer

    Measurements

    Tumor volume doubling time
    296 days
    tamoxifen regimen
    Tumor volume doubling time
    99 days
    placebo

    Source sentences

    Summary
    The calculated tumor volume doubling time (TVDT) was significantly higher in the TMX group (296 days) than in the other two groups (99 and 101 days for placebo and flutamide groups, respectively, P = .023).
    1 context sentence
    Summary · context
    Eighty-five consequent, previously untreated HCC patients with inoperable disease, were randomized to receive the luteinizing hormone-releasing hormone (LR-RH)-analogue triptorelin and the antiestrogen tamoxifen (33 patients) or triptorelin plus the antiandrogen flutamide (23 patients), or only plac…

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  4. 04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome

    In inoperable HCC, triptorelin plus tamoxifen prolonged survival compared with triptorelin plus flutamide.

    In plain wordsIn inoperable liver cancer, triptorelin plus tamoxifen prolonged survival compared with triptorelin plus flutamide.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseSurvival versus flutamide regimen
    Study

    n = 56

    Comparator
    Triptorelin plus flutamide
    Outcome group
    Mortality · Cancer

    Measurements

    Survival
    282 days
    triptorelin plus tamoxifen
    Survival
    112 days
    triptorelin plus flutamide

    Source sentences

    Summary
    The tamoxifen (TMX) group had a significantly longer survival (282 days) compared with flutamide (112 days) and with placebo (127 days) groups (P = .0238, log rank test).
    1 context sentence
    Summary · context
    Eighty-five consequent, previously untreated HCC patients with inoperable disease, were randomized to receive the luteinizing hormone-releasing hormone (LR-RH)-analogue triptorelin and the antiestrogen tamoxifen (33 patients) or triptorelin plus the antiandrogen flutamide (23 patients), or only plac…

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  5. 05HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome

    In HCC, triptorelin plus tamoxifen increased tumor volume doubling time compared with triptorelin plus flutamide.

    In plain wordsIn liver cancer, tumors doubled more slowly with triptorelin plus tamoxifen than with triptorelin plus flutamide.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseTumor volume doubling time versus flutamide regimen
    Study

    n = 56

    Comparator
    Triptorelin plus flutamide
    Outcome group
    Tumor growth · Cancer

    Measurements

    Tumor volume doubling time
    296 days
    tamoxifen regimen
    Tumor volume doubling time
    101 days
    flutamide regimen

    Source sentences

    Summary
    The calculated tumor volume doubling time (TVDT) was significantly higher in the TMX group (296 days) than in the other two groups (99 and 101 days for placebo and flutamide groups, respectively, P = .023).
    1 context sentence
    Summary · context
    Eighty-five consequent, previously untreated HCC patients with inoperable disease, were randomized to receive the luteinizing hormone-releasing hormone (LR-RH)-analogue triptorelin and the antiestrogen tamoxifen (33 patients) or triptorelin plus the antiandrogen flutamide (23 patients), or only plac…

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  6. 06HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneRandomized controlled trialEfficacy outcome

    In HCC, upper-quartile survival was at least 384 days with triptorelin plus tamoxifen, versus 170 with placebo and 134 with triptorelin plus flutamide.

    In plain wordsIn liver cancer, upper-quartile survival was longer with triptorelin plus tamoxifen than with placebo or triptorelin plus flutamide.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableUpper-quartile survival
    Study

    n: not reported in source

    Comparator
    Placebo and triptorelin plus flutamide
    Outcome group
    Mortality · Cancer

    Measurements

    Upper-quartile survival
    ≥ 384 days
    triptorelin plus tamoxifen
    Upper-quartile survival
    170 days
    placebo
    Upper-quartile survival
    134 days
    triptorelin plus flutamide

    Source sentences

    Summary
    The upper quartile of patients in the TMX group lived 384 days or longer, and most of them (57.1%) were women (P < .0005), in contrast to the upper quartile of the placebo (170 days, 16.7% women) and the flutamide group (134 days, 33.3% women).
    1 context sentence
    Summary · context
    Eighty-five consequent, previously untreated HCC patients with inoperable disease, were randomized to receive the luteinizing hormone-releasing hormone (LR-RH)-analogue triptorelin and the antiestrogen tamoxifen (33 patients) or triptorelin plus the antiandrogen flutamide (23 patients), or only plac…

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  7. 07HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyOther

    In HCC, female sex interacted with triptorelin plus tamoxifen treatment as a predictor of survival.

    In plain wordsIn liver cancer, female sex and triptorelin plus tamoxifen treatment together predicted survival.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableFemale sex by treatment interaction
    Study

    n = 85

    Outcome group
    Mortality · Cancer

    Source sentences

    Summary
    Although the degree of serum sex hormone suppression was not a significant predictor of survival, the interaction of female sex and TMX treatment, it was (P = .0052).(ABSTRACT TRUNCATED AT 250 WORDS)
    1 context sentence
    Summary · context
    Eighty-five consequent, previously untreated HCC patients with inoperable disease, were randomized to receive the luteinizing hormone-releasing hormone (LR-RH)-analogue triptorelin and the antiestrogen tamoxifen (33 patients) or triptorelin plus the antiandrogen flutamide (23 patients), or only plac…

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  8. 08HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyOther

    In HCC, women comprised 57.1% of the upper survival quartile with triptorelin plus tamoxifen, versus 16.7% with placebo and 33.3% with triptorelin plus flutamide.

    In plain wordsIn liver cancer, women formed a larger proportion of the upper survival quartile with triptorelin plus tamoxifen than with either comparator.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableFemale proportion in upper survival quartile
    Study

    n: not reported in source

    Comparator
    Placebo and triptorelin plus flutamide
    Outcome group
    Mortality · Cancer

    Measurements

    Women in upper survival quartile
    57.1%
    triptorelin plus tamoxifen
    Women in upper survival quartile
    16.7%
    placebo
    Women in upper survival quartile
    33.3%
    triptorelin plus flutamide

    Source sentences

    Summary
    The upper quartile of patients in the TMX group lived 384 days or longer, and most of them (57.1%) were women (P < .0005), in contrast to the upper quartile of the placebo (170 days, 16.7% women) and the flutamide group (134 days, 33.3% women).
    1 context sentence
    Summary · context
    Eighty-five consequent, previously untreated HCC patients with inoperable disease, were randomized to receive the luteinizing hormone-releasing hormone (LR-RH)-analogue triptorelin and the antiestrogen tamoxifen (33 patients) or triptorelin plus the antiandrogen flutamide (23 patients), or only plac…

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.